Corporate Clients

Realise potential, meet goals, and build value.

Results works as a trusted adviser to corporate clients, including some of the world’s leading pharmaceutical companies. Our clients know they can count on our track-record, depth of experience, professionalism and exceptional technical capabilities.

We work closely with corporate clients that need sector specialist advisors for their buy-side or sell-side M&A needs. Our solutions include strategic reviews of business or facility portfolios, support for acquisitions and divestments, as well as advising on licensing transactions for marketed products.

Commitment to client service is a hallmark of our project teams.

Our disciplined approach and strong technical capability allow our corporate clients to execute projects with confidence and achieve their strategic goals.

We pride ourselves on our integrity and straight talking, giving the best advice to our clients. We are focused on getting the best outcome: we think this demands an adviser who will be clear and considered however complex or pressurised the situation.

David Sanders

Managing Director


We’ve been providing independent M&A and corporate finance advice and execution services to entrepreneurs, corporates and investors in the technology and healthcare sectors for over 30 years. Whether your aim is to realise value or to find a partner for future growth, we will be your guide.


When the time comes, we’re by your side every step of the way. We help you evaluate your market, find the right buyer, and deliver the true value of your business.


With a strong track record in company carve-outs, we can help you realign your portfolio and redeploy capital to the growth of your core business.


We support clients with in-licensing, out-licensing, drug licensing, and facility licensing and we understand the complexities that are unique to licensing deals.

Equity Fundraising

We understand that optimising terms is critical, but so is finding the right partner for growth. We help articulate your equity story, target the best investors and negotiate the right deal.

Strategic Advice

Having completed over 300 transactions, we bring the breadth of perspectives and depth of business experience to provide advice on strategic options for businesses.

Recent Deals

Aug 2021
has merged with
a Vespa Capital-backed company
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Aug 2021
has acquired
Jul 2021
has received investment from
Jun 2021
has been acquired by
May 2021
has been acquired by
a Behrman Capital-backed company
May 2021
has formed a strategic alliance with
Apr 2021
has invested in

Results. Great people creating great outcomes, together.

Latest Insights

21st July 2021

Marketing Services: Global M&A and Public Company Performance H1 2021

We are pleased to share with you the H1 2021 Marketing Services Sector Review, where we analyse global M&A activity and public market performance in the marketing services sector. We continue to see very good levels of deal activity in the Marketing Services sector with H1 2021 deal volume up by 22% on H1 2020 […]

19th July 2021

The Global Technology Market Review – Q2 2021

As we predicted in Q1, deal activity has continued to increase in Q2 and the technology market remains very strong for M&A and public trading and optimism for future growth remains very healthy across all the technology sectors we track. M&A continues to be driven by strong levels of investment by private equity (directly and […]

17th May 2021

The next chapter: Changing market dynamics in commercialisation and medical communications

The last twelve months have been a time of extraordinary activity in the commercialisation sector – the COVID-19 pandemic saw medcomms groups play a crucial part in keeping pharma companies connected with patients and healthcare professionals, and dealmaking was frenetic on both sides of the Atlantic, for smaller agencies as well as for emerging ‘CCOs’. […]